New hope for rare thymic cancer: targeted drug trial launches

NCT ID NCT07324629

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum-based chemotherapy. Participants receive the drug every two weeks, and doctors will check how well it shrinks tumors and monitor side effects. The goal is to see if this drug can help when standard treatments stop working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan (Sac-TMT, also known as SKB264)
What this could lead to: If it works, this could offer a new treatment option for people with advanced thymic carcinoma who have run out of standard chemotherapy options.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects, and it is not yet known if it will shrink tumors or extend life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYMIC CARCINOMA

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.